biostudies-literatureUnknown10(9)Anderson E<h4>Background</h4>Focal treatment for prostate cancer (PCa) is a hybrid approach combining ablative treatment of the involved prostate gland and continued active surveillance (AS) of the unaffected gland. Low dose-rate (LDR) brachytherapy can be used as a lesion-targeted focal therapy, however, further studies are required to support its use. The aim of this study is to evaluate the dosimetry, toxicity and oncological outcomes of men receiving lesion-targeted focal LDR brachytherapy for low to intermediate risk PCa.<h4>Methods</h4>This is a retrospective cohort study of 26 men with unifocal, low to intermediate grade PCa diagnosed on a combination of multiparametric-magnetic resonance imaging (mp-MRI) and targeted plus template transperineal (TP) biopsy, who received focal LDR brachytheraTranslational andrology and urology3591-3603https://www.ebi.ac.uk/biostudies/studies/S-EPMC8511546biostudies-literatureFocal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution.PMC8511546Ryan ASmyth LMLAnderson EGrummet JSee AWLawrentschuk NO'Sullivan RfalseFocal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution.<h4>Background</h4>Focal treatment for prostate cancer (PCa) is a hybrid approach combining ablative treatment of the involved prostate gland and continued active surveillance (AS) of the unaffected gland. Low dose-rate (LDR) brachytherapy can be used as a lesion-targeted focal therapy, however, further studies are required to support its use. The aim of this study is to evaluate the dosimetry, toxicity and oncological outcomes of men receiving lesion-targeted focal LDR brachytherapy for low to intermediate risk PCa.<h4>Methods</h4>This is a retrospective cohort study of 26 men with unifocal, low to intermediate grade PCa diagnosed on a combination of multiparametric-magnetic resonance imaging (mp-MRI) and targeted plus template transperineal (TP) biopsy, who received focal LDR brachythera2021-01-01T00:00:00Z2021 Sep2025-04-04T09:37:34.434Z2025-04-04T09:37:34.434ZS-EPMC85115463473365510.21037/tau-21-508